Table 2.
Clinical outcomes of patients with OAL treated with ultra-low-dose RT
| Comm treatment | Patients (n = 16), n (%) |
|---|---|
| Follow-up Time (mo) | |
| Median (range) | 15.5 (5.0–30.0) |
| Best corrective visual acuity | |
| Baseline, Median (range) | 20/35 (20/20-LP) |
| Final, Median (range) | 20/30 (20/20-HM) |
| Lesion Area (mm2) | |
| Baseline | 203.8 ± 92.2 |
| Post-operation | 117.9 ± 60.4* |
| Initial evaluation post-RT | 38.7 ± 46.0# |
| One year post RT (n = 13) | |
| With regression (n = 11) | 8.5 ± 21.2# |
| With recurrence (n = 2) | 191.7 ± 13.9 |
| Local response at initial evaluation (n = 16) | |
| Complete regression | 9 (56) |
| Partial regression | 7 (44) |
| Progression | 0 (0) |
| Local response at 6 months (n = 14) | |
| Complete regression | 11 (79) |
| Partial regression | 2 (14) |
| Progression | 1 (7) |
| Time to Complete regression (mo) | |
| Median (range) | 2.0 (1.0–7.3) |
| Time to recurrence (mo) | |
| Median (range) | 7.5 (3.0–12.0) |
| Disease status at last follow-up | |
| Complete regression | 13 (81) |
| Alive with disease | 3 (19) |
| Dead due to lymphoma | 0 (0) |
| Dead due to causes other than lymphoma | 0 (0) |
| Progression-free survival at one year (%) | 85 |
| Progression-free survival (mo) | |
| Median (range) | 15.5 (5.0–24.0) |
| Ocular toxicity (n = 16) | |
| Acute toxic effect | 0 (0) |
| Chronic toxic effect | 0 (0) |
OAL ocular adnexal lymphoma, RT radiation therapy
*P < 0.01 compared with baseline lesion area; #P < 0.01 compared with postoperative lesion area